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Malaria 
Technical Appendix 
I. Detailed Methods 
All models were adjusted for neurologic treatment, as a binary variable; the predicted 
survival times have all been made for a neurologic treatment-free population (baseline 
predictions, using the –stpm2- predict –zeros- option). Intraclass correlation among parasite 
strain effects was modeled using robust standard errors via Stata’s vce(cluster clustvar) 
command (StataCorp, College Station, Texas, USA). The geographic regions were included in 
the time-to-relapse model as time-varying covariates due to extensive proportional hazard 
violations. The interaction between Old World, Temperate strains and neurologic treatment was 
significant and therefore included in the time-to-relapse model. 
The proportional hazards assumption was tested using Schoenfeld residuals and by 
assessing the parallel nature of curves in log-log plots. Both the Akaike and Bayesian 
Information Criteria (AIC/BIC) were used to assess model parsimony and goodness-of-fit. 
Finally, for all models deviance residual plots were generated, and any significant outliers were 
identified and removed from the analysis. Goodness of fit was assessed by using a visual 
comparison of the fit models to Kaplan-Meier plots; the discriminatory power of the models was 
assessed with both Harrell’s c statistic and Somer’s D statistic, with bootstrapped errors. 
Statistical analysis was performed by using Stata 12.1; all tests were 2-tailed. 
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II. Models 
 
 
Technical Appendix Figure 1. Comparison of Kaplan-Meir estimates with Royston-Parmar flexible survival 
model, incubation period. 
 
Technical Appendix Table 1. Royston-Parmar model, incubation period 
Variable Hazard ratio 95% CI p value 
Old World, Tropical 16.79 7.64–36.90 <0.001 
New World, Tropical 10.77 4.60–25.24 <0.001 
Old World, Temperate Reference – – 
New World, Temperate 7.30 3.82–13.96 <0.001 
Neurotreatment 0.98 0.68–1.39 0.989 
 
Harrell’s c statistic = 0.67 [bootstrapped 95% CI: 0.64-0.71]. 
Somer’s D statistic = 0.36 [bootstrapped 95% CI: 0.29–0.43]. 
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Technical Appendix Figure 2. Comparison of Kaplan-Meir estimates with Royston-Parmar flexible survival 
model, time-to-first relapse. 
 
Technical Appendix Table 2. Royston-Parmar model, time-to-first relapse 
Variable HR 95% CI P value 
Old World, Tropical 39.60 9.17–170.91 <0.001 
New World, Tropical 0.93 0.36–2.42 0.888 
Old World, Temperate 3.15 2.18– 4.56 <0.001 
New World, Temperate Reference – – 
Neurologic treatment 1.16 0.20–6.74 0.870 
Old World, Temperate x neurologic treatment (interaction term) 0.15 0.024–0.92 0.040 
 
Harrell’s c statistic = 0.85 [bootstrapped 95% CI: 0.76–0.93]. 
Somer’s D 0.69 [bootstrapped 95% CI: 0.54–0.84] 
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III. Distribution of Relapses 
Technical Appendix Figure 3. Comparison of the distribution of total individual relapses within 48 weeks, 
by region. 
IV. Primary Literature References 
Technical Appendix Table 3. Primary literature references 
Strain Place, date of origin Reference(s) 
Chesson Papua New Guinea, circa 1944 (1–8) 
Hlebnikovo Moscow Oblast, 1948 (9) 
Holland Netherlands, circa 1928 (10,11) 
Korea North Korea, 1953 (9) 
Leninabad Tajikistan, 1950 (9) 
Madagascar Madagascar, 1925 (11–13) 
McCoy Florida, USA, 1931 (14) 
Moscow Moscow, 1950 (9) 
NICA Nicaragua, circa 1970 (15) 
Nahicevan Azerbaijan, 1937 (9) 
Naro-Fominsk Moscow Oblast, 1946 (9) 
Panama Panama, circa 1970 (15) 
Rjazan Ryazan, Russia circa 1945 (9) 
St. Elizabeth South Carolina, USA, 1937 (3,7,16–20) 
Salvador I El Salvador, circa 1970 (15) 
Salvador II El Salvador, circa 1970 (15) 
South Vietnam Southern Vietnam, circa 1972 (21) 
Vietnam (North) Northern Vietnam, 1954 (9) 
Volgograd Volgograd, Russia, 1945 (9) 
West Pakistan Pakistan, 1968 (22) 
P. vivax multinucleatum Central China, 1965 (23) 
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